Video

New therapies bolster the melanoma armamentarium


 

Community Oncology Editor Dr. Jame Abraham spoke with Dr. Michael Postow at the Oncology Practice Summit in Las Vegas about new immuno- and targeted therapies for melanoma, their side effects, and early phase studies of emerging therapies.

The Oncology Practice Summit was the 8th annual meeting of Community Oncology, the journal of clinical issues in community practice. Dr. Abraham was a co-chair of the Summit, which was hosted this year by Community Oncology as well as The Journal of Supportive Oncology, and The Oncology Report.

Recommended Reading

Tuberous Sclerosis Skin Lesions Improved on Everolimus
MDedge Hematology and Oncology
Merkel Cell Carcinoma Prognosis Linked to Vitamin D
MDedge Hematology and Oncology
Melanoma Treatment With Vemurafenib Can Trigger Leukemia
MDedge Hematology and Oncology
Cancer deaths declined 20% since 1991
MDedge Hematology and Oncology
In Europe, melanoma is rising in men over 60
MDedge Hematology and Oncology
Aspirin may protect older women from melanoma
MDedge Hematology and Oncology
Imaging agent approved for locating lymph nodes
MDedge Hematology and Oncology
Community Oncology Podcast - Everolimus for tuberous sclerosis
MDedge Hematology and Oncology
Community Oncology Podcast - Vismodegib for advanced basal cell carcinomas
MDedge Hematology and Oncology
Vismodegib in advanced basal cell carcinoma
MDedge Hematology and Oncology

Related Articles